HOLBROOK, N.Y., October 29, 2015 -- Medgen, Inc. (OTCPink: MDIN) today announced the release of its newest product, Relaxapro™ made up of a proprietary blend of natural dietary supplements known for their calming, or anti-anxiety effects.
Anxiety effects a whopping 18% of the U.S. population, and represents a multi-billion dollar market in the U.S. alone, and yet doctors are left with few options for treating anxiety, which typically involve prescribing patients dangerous and expensive medications. Relaxapro™ contains a proprietary blend of dietary supplements that are known for combatting some of the symptoms of anxiety offering an alternative solution for those who don’t want to take prescription drugs or whose symptoms are mild enough that prescription drugs are not completely necessary. Since experts say that healthcare professionals across the US are always searching for solutions to this problem, Relaxapro™ offers Medgen an opportunity to become a powerful force in this multi-billion dollar market while helping people at the same time.
The product is now for sale online, through the company’s website, www.medgeninc.com, and will soon be available on other websites such as Amazon and Walgreens. Additionally, the company is working to get Relaxapro™ into retail stores across the U.S., along with several other Medgen products. Probably the most exciting development has been the unique distribution model being adapted for, and tested with Relaxapro™. Since the first point of contact for anxiety sufferers is usually a therapist, or medical doctor, the company has designed a unique and exciting distribution and marketing model that will put free samples of Relaxapro™ in the hands of these healthcare professionals, so that the product quickly gets to the patients who can benefit most from it. Since indications are that healthcare professionals would welcome an alternative to todays prescription drugs with open arms, the company hopes that doctors and therapists across the U.S. will soon be giving samples of Relaxapro™ to their patients, who will in-turn purchase the product online. Not only are the prescription medications potentially dangerous for the patient, they represent an ever-growing and complicated web of paperwork and procedures for doctors as the government tries to combat prescription drug abuse. As part of the new approach, the company also plans to add an auto-ordering system so that people will automatically get their Relaxapro™ every month. If successful, the same methods will be used with the other Medgen products as well.
“Free samples, and auto-ordering are just a few examples of how Medgen is starting to think outside the box.” Explained the Company’s CEO, Matthew Briggs, “We understand that to become a leader in our industry, we need to be creative and take a new approach. Giving free samples has been a successful marketing approach for prescription drug manufacturers for many years, and we see no reason it will not be successful for Medgen’s products as well.”
About Medgen, Inc.
Medgen is dedicated to producing the best alternative healthcare products to the world. The company's products include SNORenz®, SNORenz Night Time™, Stem-Intense™, and more. Most of the company's products use a unique or patented spray delivery system, and all have received rave consumer reviews all over the world, selling millions of units from 1996 to the present. For more info the company encourages people to check out www.medgeninc.com or follow the company on twitter at @medgeninc.
DISCLAIMER
This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements.